After a long regulatory process filled with delays and intense speculation, the FDA finally approved Sarepta Therapeutics Inc’s (NASDAQ:SRPT) Exondys 51 (eteplirsen) for the treatment of Duchenne Muscular Dystrophy (DMD), sending shares soaring 74% today.

No less than 13 diffrent brokerage firms weighed in on SRPT following the news. Let’s take a look and see what analysts from William Blair and RBC Capital have to say about the stock.

After much speculation and controversy about the approval of the company’s lead candidate that included a highly contested advisory committee (AdCom), additional data submissions, a delayed PDUFA date, trial design changes, and the departure of a key FDA official, William Blair analyst Tim Lugo is pleased to finally see a positive outcome from the regulators. As such, the analyst upgraded the stock from Market Perform to Outperform, and assigned an $88 price target.

Lugo noted, “We expect the company to move into a hyper-growth phase of profit generation in a DMD market with no competitive pressure. We note that comparable companies (late stage, rare disease, platform technology) such as Alnylam trade at over $6 billion and acquisitions such as Synageva were completed for $8.4 billion. We would argue that the DMD exon 51 as well as the development compounds for exon 45 and 53 holds market opportunities at least as attractive as that of the aforementioned rare-disease companies.”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Tim Lugo has a yearly average return of 6.6% and a 37% success rate. Lugo has a -31.3% average return when recommending SRPT, and is ranked #821 out of 4163 analysts.

RBC Capital analyst Simos Simeonidis fairly much echoed Lugo opinion, upgrading SRPT from Sector Perform to Outperform, while boosting the price target to $83.00 (from $5.00).

Simeonidis noted, “In one of the most perplexing regulatory decisions in recent history, FDA has granted accelerated approval to Sarepta’s eteplirsen. This decision, which may have a number of negative consequences for the review of rare disease drugs, is a major game-changer for SRPT, which we believe now becomes one of the most attractive M&A targets in biopharma, given both eteplirsen and its pipeline of exon-skipping compounds.”

As usual, we recommend taking analyst notes with a grain of salt. According to TipRanks, analyst Simos Simeonidis has a yearly average return of -35% and a 18.4% success rate. Simeonidis has a -60.6% average return when recommending SRPT, and is ranked #4038 out of 4163 analysts.